Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11304178 | 0.85 | TP53 (0.43) | TP53TDP1NFE2L2SMN1; SMN2KMT2A | |
| SCHEMBL5314108 | 0.85 | MEN1 (0.43) | TP53TDP1SMN1; SMN2KMT2AHDAC7 | |
| SCHEMBL29265305 | 0.83 | TP53 (0.41) | TP53TDP1NFE2L2SMN1; SMN2KMT2A | |
| SCHEMBL2473977 | 0.82 | FLT1 (0.41) | KMT2AHTTFLT1FLT4KDR | |
| SCHEMBL20600120 | 0.82 | LOXL2 (0.40) | NFE2L2SMN1; SMN2KMT2AHTTHDAC7 | |
| SCHEMBL28750845 | 0.80 | HDAC7 (0.37) | HDAC7HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL4586875 | 0.80 | FLT1 (0.44) | TP53SMN1; SMN2KMT2AHDAC1HDAC6 | |
| SCHEMBL6478711 | 0.80 | TDP1 (0.50) | TP53TDP1NFE2L2SMN1; SMN2KMT2A | |
| SCHEMBL14100443 | 0.78 | KAT6A (0.40) | NFE2L2SMN1; SMN2KMT2AHTTHDAC7 | |
| SCHEMBL536636 | 0.77 | PRSS1 (0.37) | HDAC1HDAC6HDAC8F2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1742942-A1 | PHENYLTHIOACETIC ACID DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005097784-A1 | PHENYLTHIOACETIC ACID DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | TP53 4884/4885TDP1 4800/4885NFE2L2 1319/4885 |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | PAH, TST, MPST | TP53 3026/4885TDP1 347/4885NFE2L2 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.